Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Overall Survival
100%
Gastrointestinal Stromal Tumor
79%
Metastatic Colorectal Cancer (mCRC)
78%
Phase II Trial
63%
Progression-free Survival
62%
Phase I Study
53%
Imatinib
50%
Chemotherapy
39%
Southwest Oncology Group
39%
Cetuximab
38%
Rare Tumors
38%
5-fluorouracil (5-FU)
38%
95% Confidence Interval
37%
Advanced Colorectal Cancer
36%
Partial Response
34%
Colorectal Cancer
34%
Ipilimumab
33%
Bevacizumab
32%
Hazard Ratio
32%
Tumor
31%
Imatinib Mesylate
31%
Leucovorin
29%
Cancer Clinical Trials
28%
Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)
27%
Clinical Trials
26%
Basket Trial
25%
Adverse Events
24%
Disease-free Survival
23%
Stable Disease
23%
Metastatic Gastrointestinal Stromal Tumor
23%
Irinotecan
23%
Overall Response Rate
22%
Advanced or Metastatic
22%
Adjuvant Therapy
22%
Response Rate
21%
Nivolumab
21%
Colorectal Cancer Prevention
21%
Gemcitabine
20%
Leukemia
20%
Targeted Therapy
20%
Complete Response
20%
Anti-PD-1 Blockade
20%
Median Overall Survival
19%
Oxaliplatin
19%
In Cancer
18%
Advanced Gastrointestinal Stromal Tumor
18%
Diarrhea
17%
National Cancer Institute
17%
Cisplatin
17%
Group Studies
16%
Medicine and Dentistry
Overall Survival
92%
Gastrointestinal Stromal Tumor
77%
Imatinib
62%
Malignant Neoplasm
61%
Progression Free Survival
61%
Diseases
60%
Oncology
56%
Metastatic Colorectal Cancer
53%
Colorectal Carcinoma
47%
Clinical Trial
47%
Phase II Trials
47%
Chemotherapy
46%
Rare Tumor
37%
Hazard Ratio
31%
Fluorouracil
31%
Arm
29%
Nivolumab
28%
Ipilimumab
28%
Cancer
26%
Neoplasm
26%
Radiation Therapy
25%
Cetuximab
25%
Adverse Event
23%
Tumor
22%
Folinic Acid
21%
CTLA-4
21%
Cisplatin
20%
Gemcitabine
19%
Recurrent Disease
18%
Colon Carcinoma
17%
Esophageal Cancer
17%
Leukemia
17%
Bevacizumab
16%
Phase III Trials
15%
Chemoradiotherapy
15%
Adenocarcinoma
15%
Irinotecan
14%
Adjuvant Therapy
14%
Disease Free Survival
14%
Targeted Therapy
13%
Non Small Cell Lung Cancer
13%
Cholangiocarcinoma
12%
Diarrhea
11%
Pancreas Cancer
11%
Trimetrexate
10%
Oxaliplatin
10%
Gastroesophageal Junction
10%
Immunotherapy
10%
Placebo
9%
Stomach
9%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
62%
Colorectal Carcinoma
48%
Progression Free Survival
44%
Diseases
40%
Fluorouracil
39%
Gastrointestinal Stromal Tumor
37%
Phase II Trials
37%
Chemotherapy Regimens
35%
Metastatic Colorectal Cancer
34%
Malignant Neoplasm
28%
Folinic Acid
26%
Imatinib
26%
Clinical Trial
25%
Neoplasm
25%
Nivolumab
23%
Ipilimumab
23%
Bevacizumab
22%
Colon Carcinoma
21%
Adverse Event
19%
Cytotoxic T Lymphocyte Antigen 4
17%
Irinotecan
16%
Disease Free Survival
15%
Recurrent Disease
15%
Cetuximab
15%
Gemcitabine
14%
Paclitaxel
14%
Celecoxib
12%
Randomized Clinical Trial
11%
Adenocarcinoma
10%
Non Small Cell Lung Cancer
10%
Diarrhea
10%
Oxaliplatin
10%
Protein Tyrosine Kinase Inhibitor
10%
Pancreas Cancer
9%
Placebo
8%
Protein Tyrosine Kinase
8%
Trimetrexate
8%
Solid Malignant Neoplasm
7%
Epidermal Growth Factor Receptor
7%
Vasculotropin
7%
Immunotherapy
7%
Neutropenia
7%
Pancreas Adenocarcinoma
7%
Cyclooxygenase 2
6%
Cisplatin
6%
Neuroendocrine Tumor
6%
Folic Acid Antagonist
6%
Phase III Trials
6%
Leukemia
6%
Capecitabine
5%